With increasing number of immunocompromised patients as well as drug resistance in fungi,
the risk of fatal fungal infections in humans increases as well. The action of echinocandins is …

Several new antifungals are currently in late-stage development, including those with novel
pharmacodynamics/mechanisms of action that represent new antifungal classes …

Rezafungin (Rezzayo™), an intravenous once-weekly echinocandin that inhibits 1, 3-β-d-
glucan synthase, is being developed by Cidara Therapeutics. In March 2023, rezafungin …

The number of antifungal classes is small, and resistance is becoming a much more
frequent problem. Much greater emphasis needs to be placed on susceptibility testing and …

Cyclic peptides are molecules that are already used as drugs in therapies approved for
various pharmacological activities, for example, as antibiotics, antifungals, anticancer, and …

Fungal infections are on the rise, driven by a growing population at risk and climate change.
Currently available antifungals include only five classes, and their utility and efficacy in …

Introduction Secondary metabolites, also called specialized metabolites, are essential in
defense and cell-to-cell communication that play a significant role in pharmacotherapy …

Antifungal resistance has become prevalent worldwide. Understanding the factors involved
in spread of resistance allows the formulation of strategies to slow resistance development …

Rezafungin is a new echinocandin under development for the treatment of candidemia and
invasive candidiasis. CLSI recently approved provisional susceptible-only breakpoints and …

Introduction: Invasive fungal infection carries a high morbidity, mortality and economic cost.
In recent times, a rising incidence of fungal infection and antifungal resistance is occurring …